Trials / Completed
CompletedNCT00038896
Study Evaluating Venlafaxine ER in Adults With Panic Disorder
A Double-blind, Placebo-controlled, Parallel-group, Flexible-dose Study of Venlafaxine Extended-release Capsules in Adult Outpatients With Panic Disorder
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 343 (actual)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to determine the efficacy, safety, and tolerability of a flexible dose of venlafaxine extended-release (ER) capsules administered for 10 weeks in the treatment of adult outpatients with panic disorder (PD) in a placebo-controlled phase III study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Venlafaxine ER |
Timeline
- Start date
- 2001-04-01
- Primary completion
- 2002-12-01
- Completion
- 2002-12-01
- First posted
- 2002-06-07
- Last updated
- 2009-08-14
Source: ClinicalTrials.gov record NCT00038896. Inclusion in this directory is not an endorsement.